LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

187 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Mai 2026, 23:41 UTC

Ergebnisse

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. Mai 2026, 21:40 UTC

Ergebnisse

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. Mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. Mai 2026, 23:12 UTC

Ergebnisse

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:07 UTC

Ergebnisse

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. Mai 2026, 23:05 UTC

Ergebnisse

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. Mai 2026, 23:04 UTC

Ergebnisse

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. Mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. Mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. Mai 2026, 21:58 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:47 UTC

Market Talk

Ergebnisse

Costco Posts 13% Sales Growth in April -- Market Talk

6. Mai 2026, 21:46 UTC

Ergebnisse

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. Mai 2026, 21:40 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. Mai 2026, 21:32 UTC

Heiße Aktien

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. Mai 2026, 21:29 UTC

Ergebnisse

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

187 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.